Developer docs
API playgroundTry for free, no card

Search company profiles

Strides Pharma Inc.

Full company profile

uuid00yntj5

Namestring
Strides Pharma Inc.
Legal namestring
Strides Pharma Inc.
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Strides Pharma Inc. is the US-based commercial and manufacturing subsidiary of India-headquartered Strides Pharma Science Limited, operating from 200 Crossing Boulevard, Suite 110 in Bridgewater, NJ (commercial) and 1 Ram Ridge Road in Chestnut Ridge, NY (manufacturing), with the parent's innovative R&D hub in Bangalore feeding the pipeline. The company specializes in generic pharmaceutical products across multiple dosage forms: soft-gel capsules (SGC), oral solids, modified releases, topicals, and liquids, and operates cGMP-compliant facilities including a chestnut ridge site cleared by USFDA under Voluntary Action Indicated (VAI) classification following its December 2025 inspection. Its 14-product US portfolio spans cardiovascular (Amlodipine/Valsartan/HCTZ), respiratory (Benzonatate), mental health (Buspirone HCl, Doxepin HCl), endocrine/metabolic (Calcitriol, Methimazole, Megestrol Acetate, Testosterone Gel), anti-inflammatory/immunosuppressant (Hydrocortisone, Mycophenolate Mofetil, Children's Ibuprofen), and gastrointestinal (Omeprazole/Sodium Bicarbonate, PEG bowel preparations) categories, with Wholesale Acquisition Cost pricing disclosed by strength and pack size.

Revenue is generated through B2B direct sales to US healthcare providers, pharmacies, pharmacy chains, and pharmaceutical distributors, with tiered unit pricing, minimum order quantities on certain SKUs, and contract manufacturing relationships (e.g., Taro Pharmaceuticals USA for Children's Ibuprofen Oral Suspension). The go-to-market is sales-led and the customer model is horizontal across the US generics market. Product breadth is supported by the parent's integrated value chain — from formulation R&D through commercial launch — and recently expanded by drug-device combination nasal spray capabilities cleared in pre-approval inspection.

Short descriptiontext

Strides Pharma Inc., the US subsidiary of India-based Strides Pharma Science Limited, develops and manufactures generic pharmaceuticals in soft-gel capsules, oral solids, modified releases, topicals, and liquids for sale to US healthcare providers, pharmacies, and distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBridgewater, United States
HQ citystring
Bridgewater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, soft-gel capsules, oral solid dosage, modified release formulations, topical drug manufacturing
Industry2 codes
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Products
TypeOne Time License
Description

Strides Pharma generates revenue through the manufacture and sale of generic pharmaceutical products including soft-gel capsules, oral solids, modified releases, topicals, and liquids. Revenue is derived from one-time product transactions to B2B customers (healthcare providers, pharmacies, distributors).

stridespharmausa.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details6 tiers
1Benzonatate Capsules 100mg - WAC $29.95 (100ct), $115.00 (500ct)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Benzonatate 100mg capsules: $29.95 per 100 count, $115.00 per 500 count. MOQ 96 units.

stridespharmausa.com
2Benzonatate Capsules 200mg - WAC $42.50 (100ct), $158.48 (500ct)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Benzonatate 200mg capsules: $42.50 per 100 count, $158.48 per 500 count. MOQ 48 units.

stridespharmausa.com
3Calcitriol Capsules 0.25mcg - WAC $28.81 (30ct), $94.59 (100ct)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Calcitriol 0.25mcg capsules: $28.81 per 30 count, $94.59 per 100 count.

stridespharmausa.com
4Buspirone HCl Tablets 5mg - WAC $4.80 (100ct), $24.26 (500ct), $31.97 (1000ct)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Buspirone HCl 5mg tablets: $4.80/100ct, $24.26/500ct, $31.97/1000ct. Brand reference: Buspar.

stridespharmausa.com
5Amlodipine/Valsartan/HCTZ Tablets - WAC $239.29 to $344.60 (30ct)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Amlodipine/Valsartan/HCTZ tablets: $239.29-$344.60 per 30 count depending on strength. Brand reference: Exforge HCT.

stridespharmausa.com
6Testosterone Gel - WAC $180.00 (25mg/2.5G 30ct), $190.00 (50mg/5G 30ct)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Testosterone Gel 1%: $180.00 for 25mg/2.5G 30-count, $190.00 for 50mg/5G 30-count. Brand reference: Androgel.

stridespharmausa.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Strides Pharma Inc. develops, manufactures, and supplies generic pharmaceutical products across multiple dosage forms including soft-gel capsules (SGC), oral solids, modified releases, topicals, and liquids. Operating as the US-based front-end of Strides Pharma Science Limited, the company sells cGMP-compliant generic medications to healthcare providers, pharmacies, and distributors in the US Rx market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FDA inspection closed with Voluntary Action Indicated (VAI) classification, strengthening US business and near-term growth prospects
Product overview1 text field

Strides Pharma Inc. is the US-based pharmaceutical business of Strides Pharma Science Limited, specializing in generic pharmaceutical products. The company focuses on soft-gel capsules (SGC), oral solids, modified releases, topicals, liquids, and high-competition products with integrated value chain benefits. Their product portfolio includes 14 distinct pharmaceutical products across multiple therapeutic categories: cardiovascular medications (Amlodipine/Valsartan/HCTZ, Testosterone Gel), respiratory (Benzonatate Capsules), mental health (Buspirone HCl Tablets, Doxepin Hydrochloride Tablets), endocrine/metabolic (Calcitriol Capsules, Methimazole Tablets, Megestrol Acetate OS), anti-inflammatory (Hydrocortisone Tablets, Children's Ibuprofen Oral Suspension), immunosuppressant (Mycophenolate Mofetil Tablets), gastrointestinal (Omeprazole & Sodium Bicarbonate, PEG solutions), and OTC consumer health products.

Product and service14 records
1Amlodipine/Valsartan/Hydrochlorothiazide Tablets
CategoryGeneric Pharmaceuticals - Cardiovascular
2Benzonatate Capsules
CategoryGeneric Pharmaceuticals - Respiratory
3Buspirone HCl Tablets
CategoryGeneric Pharmaceuticals - Mental Health
4Calcitriol Capsules
CategoryGeneric Pharmaceuticals - Endocrine/Metabolic
5Doxepin Hydrochloride Tablets
CategoryGeneric Pharmaceuticals - Mental Health
6Hydrocortisone Tablets
CategoryGeneric Pharmaceuticals - Anti-inflammatory
7Megestrol Acetate Oral Suspension
CategoryGeneric Pharmaceuticals - Endocrine/Oncology
8Methimazole Tablets
CategoryGeneric Pharmaceuticals - Endocrine
9Mycophenolate Mofetil Tablets
CategoryGeneric Pharmaceuticals - Immunosuppressant
10Omeprazole & Sodium Bicarbonate for Oral Suspension
CategoryGeneric Pharmaceuticals - Gastrointestinal
11PEG (GoLyTELY)
CategoryGeneric Pharmaceuticals - Gastrointestinal
12PEG (Nulytely)
CategoryGeneric Pharmaceuticals - Gastrointestinal
13Testosterone Gel
CategoryGeneric Pharmaceuticals - Hormone Therapy
14Children's Ibuprofen Oral Suspension
CategoryGeneric Pharmaceuticals - OTC Consumer Health
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-headquartered multinational with significant US generics operations including specialty formulations; comparable on parent-subsidiary US structure, integrated R&D-to-commercial value chain, and broad generic therapeutic portfolio.

TypeDirect peer
Description

Israel-based global generic pharmaceutical manufacturer with major US operations; directly comparable as a US-focused generic manufacturer across dosage forms including soft-gels, and a named customer relationship partner of Strides.

TypeDirect peer
Description

US-based vertically integrated generic and specialty pharmaceutical manufacturer; comparable on dosage-form breadth (oral solids, injectables, topicals) and US-centric B2B distribution model.

TypeDirect peer
Description

Canadian-headquartered generic pharmaceutical manufacturer with significant US operations; comparable on dosage-form breadth (oral solids, liquids, topicals) and FDA-regulated B2B supply to US pharmacies.

TypeDirect peer
Description

India-headquartered global generics manufacturer with US commercial operations; comparable on integrated value chain, India R&D, and broad US generic product portfolio across multiple therapeutic categories.

TypeDirect peer
Description

US subsidiary of India's Cadila/Zydus group; comparable as an Indian-parented US generics manufacturer across dosage forms including injectables and specialty products targeting the same pharmacy and institutional buyers.

TypeBroad incumbent
Description

MNC generic and specialty pharmaceutical manufacturer with US operations across oral solids, injectables, and specialty dosage forms; broader incumbent offering overlapping generic categories and institutional distribution comparable to Strides' offering.

TypeBroad incumbent
Description

US specialty/generic pharmaceutical manufacturer (parent of Par Pharmaceutical); comparable on US-market generics portfolio, focus on complex generics including modified-release formulations, and B2B distribution to pharmacies.

TypeDirect peer
Description

US arm of India-headquartered Aurobindo Pharma; comparable as an Indian-parented US generic manufacturer offering oral solids, injectables, and specialty dosage forms across the same buyer base as Strides.

TypeDirect peer
Description

Indian generic manufacturer with substantial US commercial and manufacturing footprint; directly comparable on product categories (oral solids, specialty), India R&D backbone, and US B2B distribution model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Strides Pharma Inc.

Generic Pharmaceuticals Manufacturingstridespharmausa.com

Strides Pharma Inc., the US subsidiary of India-based Strides Pharma Science Limited, develops and manufactures generic pharmaceuticals in soft-gel capsules, oral solids, modified releases, topicals, and liquids for sale to US healthcare providers, pharmacies, and distributors.

What Strides Pharma Inc. does

Strides Pharma Inc. is the US-based commercial and manufacturing subsidiary of India-headquartered Strides Pharma Science Limited, operating from 200 Crossing Boulevard, Suite 110 in Bridgewater, NJ (commercial) and 1 Ram Ridge Road in Chestnut Ridge, NY (manufacturing), with the parent's innovative R&D hub in Bangalore feeding the pipeline. The company specializes in generic pharmaceutical products across multiple dosage forms: soft-gel capsules (SGC), oral solids, modified releases, topicals, and liquids, and operates cGMP-compliant facilities including a chestnut ridge site cleared by USFDA under Voluntary Action Indicated (VAI) classification following its December 2025 inspection. Its 14-product US portfolio spans cardiovascular (Amlodipine/Valsartan/HCTZ), respiratory (Benzonatate), mental health (Buspirone HCl, Doxepin HCl), endocrine/metabolic (Calcitriol, Methimazole, Megestrol Acetate, Testosterone Gel), anti-inflammatory/immunosuppressant (Hydrocortisone, Mycophenolate Mofetil, Children's Ibuprofen), and gastrointestinal (Omeprazole/Sodium Bicarbonate, PEG bowel preparations) categories, with Wholesale Acquisition Cost pricing disclosed by strength and pack size.

Revenue is generated through B2B direct sales to US healthcare providers, pharmacies, pharmacy chains, and pharmaceutical distributors, with tiered unit pricing, minimum order quantities on certain SKUs, and contract manufacturing relationships (e.g., Taro Pharmaceuticals USA for Children's Ibuprofen Oral Suspension). The go-to-market is sales-led and the customer model is horizontal across the US generics market. Product breadth is supported by the parent's integrated value chain — from formulation R&D through commercial launch — and recently expanded by drug-device combination nasal spray capabilities cleared in pre-approval inspection.

Strides Pharma Inc. firmographics

Firmographics
Name
Strides Pharma Inc.
Legal name
Strides Pharma Inc.
Website
https://stridespharmausa.com
Company type
Private
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Strides Pharma Inc., the US subsidiary of India-based Strides Pharma Science Limited, develops and manufactures generic pharmaceuticals in soft-gel capsules, oral solids, modified releases, topicals, and liquids for sale to US healthcare providers, pharmacies, and distributors.
Ownership category
akta.pro rank

Strides Pharma Inc. industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Soft-gel capsules
  • Oral solid dosage
  • Modified release formulations
  • Topical drug manufacturing

Where Strides Pharma Inc. is headquartered

Location

Headquarters

HQ city
Bridgewater
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Strides Pharma Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Generic Pharmaceutical Products: Strides Pharma generates revenue through the manufacture and sale of generic pharmaceutical products including soft-gel capsules, oral solids, modified releases, topicals, and liquids. Revenue is derived from one-time product transactions to B2B customers (healthcare providers, pharmacies, distributors).

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goBenzonatate Capsules 100mg - WAC $29.95 (100ct), $115.00 (500ct)
Unit PricingPay-as-you-goBenzonatate Capsules 200mg - WAC $42.50 (100ct), $158.48 (500ct)
Unit PricingPay-as-you-goCalcitriol Capsules 0.25mcg - WAC $28.81 (30ct), $94.59 (100ct)
Unit PricingPay-as-you-goBuspirone HCl Tablets 5mg - WAC $4.80 (100ct), $24.26 (500ct), $31.97 (1000ct)
Unit PricingPay-as-you-goAmlodipine/Valsartan/HCTZ Tablets - WAC $239.29 to $344.60 (30ct)
Unit PricingPay-as-you-goTestosterone Gel - WAC $180.00 (25mg/2.5G 30ct), $190.00 (50mg/5G 30ct)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Strides Pharma Inc. product offering

Product offering

Core offering

Strides Pharma Inc. develops, manufactures, and supplies generic pharmaceutical products across multiple dosage forms including soft-gel capsules (SGC), oral solids, modified releases, topicals, and liquids. Operating as the US-based front-end of Strides Pharma Science Limited, the company sells cGMP-compliant generic medications to healthcare providers, pharmacies, and distributors in the US Rx market.

Product overview

Strides Pharma Inc. is the US-based pharmaceutical business of Strides Pharma Science Limited, specializing in generic pharmaceutical products. The company focuses on soft-gel capsules (SGC), oral solids, modified releases, topicals, liquids, and high-competition products with integrated value chain benefits. Their product portfolio includes 14 distinct pharmaceutical products across multiple therapeutic categories: cardiovascular medications (Amlodipine/Valsartan/HCTZ, Testosterone Gel), respiratory (Benzonatate Capsules), mental health (Buspirone HCl Tablets, Doxepin Hydrochloride Tablets), endocrine/metabolic (Calcitriol Capsules, Methimazole Tablets, Megestrol Acetate OS), anti-inflammatory (Hydrocortisone Tablets, Children's Ibuprofen Oral Suspension), immunosuppressant (Mycophenolate Mofetil Tablets), gastrointestinal (Omeprazole & Sodium Bicarbonate, PEG solutions), and OTC consumer health products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Amlodipine/Valsartan/Hydrochlorothiazide Tablets
  • Benzonatate Capsules
  • Buspirone HCl Tablets
  • Calcitriol Capsules
  • Doxepin Hydrochloride Tablets
  • Hydrocortisone Tablets
  • Megestrol Acetate Oral Suspension
  • Methimazole Tablets
  • Mycophenolate Mofetil Tablets
  • Omeprazole & Sodium Bicarbonate for Oral Suspension
  • PEG (GoLyTELY)
  • PEG (Nulytely)
  • Testosterone Gel
  • Children's Ibuprofen Oral Suspension

Quantifiable outcome

  • FDA inspection closed with Voluntary Action Indicated (VAI) classification, strengthening US business and near-term growth prospects

Companies that use Strides Pharma Inc.

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Strides Pharma Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Strides Pharma Inc. partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Strides Pharma Inc. competitors and assessment

Company assessment

Direct peers

  • Dr. Reddy's Laboratories: India-headquartered multinational with significant US generics operations including specialty formulations; comparable on parent-subsidiary US structure, integrated R&D-to-commercial value chain, and broad generic therapeutic portfolio.
  • Taro Pharmaceutical Industries: Israel-based global generic pharmaceutical manufacturer with major US operations; directly comparable as a US-focused generic manufacturer across dosage forms including soft-gels, and a named customer relationship partner of Strides.
  • Amneal Pharmaceuticals: US-based vertically integrated generic and specialty pharmaceutical manufacturer; comparable on dosage-form breadth (oral solids, injectables, topicals) and US-centric B2B distribution model.
  • Apotex Corp. Canadian-headquartered generic pharmaceutical manufacturer with significant US operations; comparable on dosage-form breadth (oral solids, liquids, topicals) and FDA-regulated B2B supply to US pharmacies.
  • Glenmark Pharmaceuticals: India-headquartered global generics manufacturer with US commercial operations; comparable on integrated value chain, India R&D, and broad US generic product portfolio across multiple therapeutic categories.
  • Zydus Pharmaceuticals (USA): US subsidiary of India's Cadila/Zydus group; comparable as an Indian-parented US generics manufacturer across dosage forms including injectables and specialty products targeting the same pharmacy and institutional buyers.
  • Aurobindo Pharma USA: US arm of India-headquartered Aurobindo Pharma; comparable as an Indian-parented US generic manufacturer offering oral solids, injectables, and specialty dosage forms across the same buyer base as Strides.
  • Lupin Pharmaceuticals: Indian generic manufacturer with substantial US commercial and manufacturing footprint; directly comparable on product categories (oral solids, specialty), India R&D backbone, and US B2B distribution model.

Broad incumbents

  • Hikma Pharmaceuticals: MNC generic and specialty pharmaceutical manufacturer with US operations across oral solids, injectables, and specialty dosage forms; broader incumbent offering overlapping generic categories and institutional distribution comparable to Strides' offering.
  • Endo International (Par Pharmaceutical): US specialty/generic pharmaceutical manufacturer (parent of Par Pharmaceutical); comparable on US-market generics portfolio, focus on complex generics including modified-release formulations, and B2B distribution to pharmacies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Strides Pharma Inc. social profiles

Digital presence

Strides Pharma Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Strides Pharma Inc. leadership team

Management profile

Number of profiles

Strides Pharma Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Strides Pharma Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strides Pharma Inc.

What does Strides Pharma Inc. do?

Strides Pharma Inc. develops, manufactures, and supplies generic pharmaceutical products across multiple dosage forms including soft-gel capsules (SGC), oral solids, modified releases, topicals, and liquids. Operating as the US-based front-end of Strides Pharma Science Limited, the company sells cGMP-compliant generic medications to healthcare providers, pharmacies, and distributors in the US Rx market.

Is Strides Pharma Inc. a public or private company?

Strides Pharma Inc. is a private company. It is classified as corporate owned and is currently operating.

When was Strides Pharma Inc. founded?

Strides Pharma Inc. was founded in -1. It employs 501 to 1,000 people.

Where is Strides Pharma Inc. based?

Strides Pharma Inc. is headquartered in Bridgewater, United States, in the North America region.

How does Strides Pharma Inc. make money?

One revenue line is on record: generic Pharmaceutical Products.

Who are Strides Pharma Inc.'s main competitors?

Direct peers on record are Dr. Reddy's Laboratories, Taro Pharmaceutical Industries, Amneal Pharmaceuticals, Apotex Corp., Glenmark Pharmaceuticals, Zydus Pharmaceuticals (USA), Aurobindo Pharma USA and Lupin Pharmaceuticals. Broad incumbents are Hikma Pharmaceuticals and Endo International (Par Pharmaceutical).

Does Strides Pharma Inc. have an API?

No public API is recorded for Strides Pharma Inc..

What industry is Strides Pharma Inc. in?

Strides Pharma Inc.'s product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GizmodoFDA Recalls Nearly 90,000 Children’s Ibuprofen Bottles Over ‘Gel-Like Mass’The FDA announced a recall of Taro Pharmaceuticals' Children's Ibuprofen Oral Suspension products manufactured by Strides Pharma Inc. after bottles were found to contain black particles and a "gel-like mass." The recall affects nearly 90,000 bottles across two lots (7261973A and 7261974A) distributed nationwide, with an expiration date of January 31, 2027. The FDA has designated this a Class II recall, indicating potential temporary or medically reversible adverse health consequences for children ages 2 to 11 who used the contaminated product.MedicalxpressNearly 90,000 bottles of children's ibuprofen recalled nationwideNearly 90,000 bottles of Children's Ibuprofen Oral Suspension have been recalled nationwide due to possible contamination with foreign substances, including a gel-like mass and black particles. The recall affects 89,592 bottles manufactured by Strides Pharma for Taro Pharmaceuticals USA, Inc., specifically lot numbers 7261973A and 7261974A with an expiration date of Jan. 31, 2027. The FDA classified it as a Class II recall, indicating temporary or medically reversible health risks but a low probability of serious harm.UsnewsNearly 90,000 Bottles of Children’s Ibuprofen Recalled NationwideStrides Pharma has recalled 89,592 bottles of Children\'s Ibuprofen Oral Suspension manufactured for Taro Pharmaceuticals USA, Inc., after receiving complaints about a gel-like mass and black particles found inside the medicine. The affected lot numbers 7261973A and 7261974A, with an expiration date of Jan. 31, 2027, were distributed nationwide and the recall was initiated on March 2. The FDA has classified this as a Class II recall, indicating temporary or medically reversible health risks but low probability of serious harm.Boston HeraldTicker: Children’s pain reliever recalled; Qatar halts helium outputNearly 90,000 bottles of Taro Pharmaceuticals’ children's ibuprofen were recalled due to contamination reports, with the recall initiated by Strides Pharma Inc. after consumer reports of black particles. Iran's attack on Qatar’s natural gas facilities threatens to disrupt global helium supplies, as Qatar accounts for a third of the world's helium production.New Indian ExpressUS FDA recalls nearly 90,000 bottles of India-made children's Ibuprofen oral medicationNearly 90,000 bottles of Taro Pharmaceuticals' Children's Ibuprofen Oral Suspension have been recalled after customers reported finding gel-like masses and black particles in the product. Strides Pharma Inc., the India-based contract manufacturer, initiated the recall earlier this month, with the FDA posting the notice and classifying the risk of serious health consequences to consumers as "remote." The recall affects a berry-flavored pain reliever marketed for children ages 2 to 11.UsnewsNearly 90,000 Bottles of Children's Liquid Pain Medication RecalledThe FDA announced a recall of nearly 90,000 bottles of Taro Pharmaceuticals' Children's Ibuprofen Oral Suspension after customers reported finding a gel-like mass and black particles in the product. Strides Pharma Inc., the India-based manufacturer, initiated the recall, which regulators categorized as carrying a "remote" risk of serious health consequences to children. The berry-flavored pain reliever was intended for children ages 2 to 11.Fast CompanyChildren’s ibuprofen recalled nationwide after customer complaints of ‘gel-like mass and black particles’Strides Pharma Inc. has recalled 89,952 bottles of Children's Ibuprofen Oral Suspension across the United States following customer complaints of a gel-like mass and black particles in the medication. The recall, initiated on March 2, 2026, was classified as a Class II recall by the FDA on March 16, indicating potential temporary or reversible adverse health consequences. The India-based manufacturer produced the ibuprofen for Taro Pharmaceuticals U.S.A., Inc., headquartered in Hawthorne, New York.Idaho Business ReviewChildren’s ibuprofen recalled nationwide including Idaho for contaminationStrides Pharma initiated a nationwide recall of 89,592 bottles of Children’s Ibuprofen Oral Suspension on March 2 after discovering a gel-like mass and black particles in the product. The FDA classified this as a Class II recall on March 16, meaning there is a risk of temporary or medically reversible adverse health consequences. The investigation is ongoing as of March 20, and consumers are advised to stop using the recalled product immediately.The Times of IndiaChildren’s ibuprofen recalled in 2026: Nearly 90,000 bottles of pain-relieving medication pulled nationwide - The Economic TimesThe US FDA classified a Class II recall for nearly 90,000 bottles of children's ibuprofen oral suspension after the medication was found to contain foreign substances, including a gel-like mass and black particles. The contaminated product was manufactured in India, distributed by Strides Pharma Inc., and manufactured for Taro Pharmaceuticals U.S.A., Inc., with the recall voluntarily initiated on March 2, 2026. The affected lots (7261973A and 7261974A) were distributed nationwide across the United States with an expiry date of January 31, 2027.